Posted On: 12/05/2016 3:13:02 PM
Post# of 72446
Re: Loose Lips #29198
I think the K-OC trial will take place in the US. The reference is to APR-246.
"Now called APR-246, in 2012 it made it through the first round of safety trials on patients with a type of blood cancer that shows high rates of mutations in p53. It is now in a phase II clinical trial in women with ovarian cancer, which almost always has p53 mutations. The trial, at centers across Europe, will likely be completed within 2 years, says Lars Abrahmsen, Aprea AB's chief scientific officer in Stockholm."
"Side effects are a concern because APR-246 binds to the amino acid cysteine and irrevocably changes it—and cysteines are abundant on numerous other proteins besides p53. But so far, Abrahmsen says, APR-246 has been tolerated well in clinical trials, even in relatively high doses."
K was mentioned in the comments.
"Now called APR-246, in 2012 it made it through the first round of safety trials on patients with a type of blood cancer that shows high rates of mutations in p53. It is now in a phase II clinical trial in women with ovarian cancer, which almost always has p53 mutations. The trial, at centers across Europe, will likely be completed within 2 years, says Lars Abrahmsen, Aprea AB's chief scientific officer in Stockholm."
"Side effects are a concern because APR-246 binds to the amino acid cysteine and irrevocably changes it—and cysteines are abundant on numerous other proteins besides p53. But so far, Abrahmsen says, APR-246 has been tolerated well in clinical trials, even in relatively high doses."
K was mentioned in the comments.
(0)
(0)
